Sign In
Buy EYPT
$12.34
-0.190 (-1.52%)
At Close: Jun 03, 2026
Week In Review: Innovent Out-Licenses Ex-China Rights For PD-1 To Lilly In $1 Billion Deal
08:36am, Sunday, 23'rd Aug 2020
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 19)
10X Genomics Inc (NASDAQ: TXG)
ALX Oncology Holdings Inc (NASDAQ: ALXO)
Avenue Therapeutics Inc (NASDAQ: ATXI)...
The Daily Biotech Pulse: Gilead's Filgotinib Stumbles With FDA, J&J Laps Up Momenta In $6.5B Deal, 2 IPOs
12:00am, Wednesday, 19'th Aug 2020
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 18)
Avenue Therapeutics Inc (NASDAQ: ATXI)
Checkmate Pharmaceuticals Inc (NASDAQ: CMPI)
DarioHealth Corp (NASDAQ:...
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 17)
Catalent Inc (NYSE: CTLT)
CureVac N.V. (NASDAQ: CVAC) (follow-on buying after a 250% advance on its debut Friday...
Eyepoint Pharmaceuticals’ (EYPT) Hold Rating Reaffirmed at HC Wainwright
07:58am, Sunday, 09'th Aug 2020
Eyepoint Pharmaceuticals (NASDAQ:EYPT)‘s stock had its “hold” rating restated by research analysts at HC Wainwright in a note issued to investors on Thursday, TipRanks reports. EYPT has been the
EyePoint Pharmaceuticals (EYPT) Receives a Hold from H.C. Wainwright - Markets
10:42am, Thursday, 06'th Aug 2020
In a report released today, Yi Chen from H.C. Wainwright reiterated a Hold rating on EyePoint Pharmaceuticals (EYPT – Research
EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Tops Revenue Estimates
01:25pm, Wednesday, 05'th Aug 2020
EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of 9.09% and 46.69%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
EyePoint Pharmaceuticals: Q4 Earnings Insights
12:19pm, Wednesday, 05'th Aug 2020
Shares of EyePoint Pharmaceuticals (NASDAQ:EYPT) moved lower by 2.5% in pre-market trading after the company reported Q4 results.Quarterly Results Earnings per share increased 9.09% year over year to
EyePoint Pharmaceuticals Reports Second Quarter 2020 Financial Results and Highlights Recent Corporate Developments
11:00am, Wednesday, 05'th Aug 2020
\- Total revenues of $4.1 million and net product revenues of $3.7 million impacted by COVID-19 pandemic - \- U.S. commercial alliance with ImprimisRx to expand reach of DEXYCU® -\- Jay S. Duker,
The Daily Biotech Pulse: Novavax Vaccine Data, Aerpio Gets $5.1M Funding For COVID Trial, Rigel Gains Big On Earnings
12:00am, Wednesday, 05'th Aug 2020
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 4)
ABIOMED, Inc. (NASDAQ: ABMD) (FDA approved the emergency use of Abiomed's Impella heart pump in combination...
The Week Ahead In Biotech: Novavax Coronavirus Vaccine Readout, FDA Decisions And More Earnings
12:00am, Sunday, 02'nd Aug 2020
Biotech stocks came under pressure in the week ended July 31 amid mixed earnings from the sector and some adverse clinical readouts.
COVID-19 news flow continued to pour in,...
EyePoint Pharmaceuticals Announces Second Quarter 2020 Financial Results Release Date and Conference Call Information
11:00am, Wednesday, 29'th Jul 2020
WATERTOWN, Mass., July 29, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products,
WATERTOWN, Mass., July 27, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products,
\- World-renowned retina specialist to lead EYP-1901 development efforts and support expansion of EyePoint’s ocular disease pipeline - WATERTOWN, Mass., July 13, 2020 --.
Outlook of Diabetic Macular Edema (DME) 2020-2025 - Current Landscape and the Way Forward - ResearchAndMarkets.com
12:00am, Monday, 13'th Jul 2020
The
